



ASX ANNOUNCEMENT

18 November 2013

CHANGE OF NAME & ASX CODE: CYNATA THERAPEUTICS LIMITED

The Board is pleased to advise that effective today the Company's name has changed to Cynata Therapeutics Limited (formerly Eco Quest Limited).

The ASX codes for the Company's securities have changed as follows:

Class of securities	Previous ASX code	New ASX Code
Ordinary fully paid	ECQ	CYP
Listed options-exercisable at 20 cents on or before 31 December 2014	ECQO	CYPO

Shareholders approved the change of the Company's name to Cynata Therapeutics Limited at the Annual General Meeting held on 29 October 2013.

Dr Ross Macdonald

Managing Director & Chief Executive Officer
+61 412 119 343

About Cynata Therapeutics Limited

Cynata Therapeutics Ltd is an Australian stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus™, originating from the University of Wisconsin-Madison, a world leader in stem cell research. The proprietary Cymerus™ technology seeks to address a critical shortcoming in existing methods of production of mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve economic manufacture at commercial scale. Cymerus™ does so through the production of a particular type of MSC precursor, called a mesenchymoangioblast (MCA). The Cymerus™ MCA platform provides a source of MSCs that is independent of donor limitations and provides a potential "off-the-shelf" stem cell platform for therapeutic product use, with a pharmaceutical business model and economies of scale. This has the potential to create a new standard in the emergent arena of stem cell therapeutics and provides both a unique differentiator and an important competitive position.